Get the Stockscreener App
78.49
1.89%
-1.51
Pre-market:
80.25
1.76
+2.24%
Edwards Lifesciences Corp stock is traded at $78.49, with a volume of 6.02M.
It is down -1.89% in the last 24 hours and up +0.36% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$80.00
Open:
$80.45
24h Volume:
6.02M
Relative Volume:
1.35
Market Cap:
$46.04B
Revenue:
$5.69B
Net Income/Loss:
$4.15B
P/E Ratio:
11.29
EPS:
6.95
Net Cash Flow:
$623.10M
1W Performance:
+2.52%
1M Performance:
+0.36%
6M Performance:
+8.17%
1Y Performance:
+25.85%
1-Day Range:
$78.37
$80.73
1-Week Range:
$75.39
$83.00
52-Week Range:
$59.41
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
78.49 | 46.93B | 5.69B | 4.15B | 623.10M | 6.95 |
|
ABT
Abbott Laboratories
|
126.35 | 220.16B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.84 | 157.03B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
400.69 | 154.21B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.97 | 119.08B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences Corporation (NYSE:EW) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts upgrade Edwards as TAVR segment improves - MassDevice
BTIG upgrades Edwards Lifesciences stock to Buy on TAVR segment stability - Investing.com
Edwards Lifesciences prevails in heart valve dispute at the UPC - JUVE Patent
Edwards Lifesciences Insider Makes a Major Stock Move! - TipRanks
Edwards Lifesciences Reports Strong Growth and Raises Guidance - TipRanks
Edwards Lifesciences debuts heart valve failure PSA as Rams training camp begins - Medical Marketing and Media
Edwards Lifesciences stock price target raised to $85 by Bernstein - Investing.com
Edwards Lifesciences stock price target raised to $85 by UBS on strong TAVR sales - Investing.com
Edwards Lifesciences’ SWOT analysis: strong TAVR growth boosts stock outlook - Investing.com
When is Edwards Lifesciences Corporation stock expected to show significant growthExceptional return forecasts - jammulinksnews.com
Is Edwards Lifesciences Corporation a growth stock or a value stockDiscover breakthrough stocks before the crowd - jammulinksnews.com
How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - jammulinksnews.com
Edwards Lifesciences (EW) Announces Executive Leadership Change - GuruFocus
Can Edwards Lifesciences Corporation stock recover from recent declineTriple Return With Stability - metal.it
Edwards Lifesciences stock price target raised to $90 by Piper Sandler - Investing.com
Earnings Preview: What To Expect From Edwards Lifesciences' Report - MSN
Edwards Lifesciences Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - uk.finance.yahoo.com
Edwards Lifesciences stock price target raised to $84 from $75 at TD Cowen - Investing.com
Edwards Lifesciences stock price target raised to $89 at RBC on growth outlook - Investing.com
JPMorgan Adjusts Edwards Lifesciences (EW) Price Target Followin - GuruFocus
Edwards Lifesciences (EW) Target Price Raised by JP Morgan | EW Stock News - GuruFocus
Edwards Lifesciences sales up nearly 12% in Q2 - MassDevice
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corporation Stock Analysis and ForecastPhenomenal returns - PrintWeekIndia
Edwards Lifesciences Q2 EarningsEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Exec Larry Wood Departs for Procept BioRobotics - Orange County Business Journal
Edwards Lifesciences (EW) Target Price Raised by Baird Analyst | - GuruFocus
Edwards Lifesciences’ MITRIS Valve Study: A Key Development for Investors - TipRanks
Edwards Lifesciences stock reaches 52-week high at 81.86 USD - Investing.com
Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Benzinga
Edwards Lifesciences (EW) Surpasses Earnings and Revenue Expecta - GuruFocus
Edwards Lifesciences Q2 2025 Earnings Report - MarketBeat
Edwards Lifesciences (EW) Receives Price Target Upgrade from Deutsche Bank | EW Stock News - GuruFocus
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW) - Yahoo Finance
Edwards Lifesciences (EW) Receives Price Target Boost from Baird | EW Stock News - GuruFocus
JPMorgan Adjusts Edwards Lifesciences (EW) Price Target Following Strong Q2 Results | EW Stock News - GuruFocus
Edwards loses longtime TAVR leader Larry Wood - Yahoo Finance
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised ... - Yahoo Finance
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised ... By GuruFocus - Investing.com Canada
Edwards Lifesciences Corp (EW) Q2 2025 Earnings Call Highlights: Strong Sales Growth and Raised Guidance - GuruFocus
Edwards Lifesciences Reports Strong Q2 Growth - TipRanks
Earnings call transcript: Edwards Lifesciences Q2 2025 beats forecasts, stock dips - Investing.com
Earnings call transcript: Edwards Lifesciences Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Edwards Lifesciences (EW) Surges After Earnings Report | EW Stock News - GuruFocus
After-hours movers: Edwards Lifesciences, Intel, Deckers Brands and more - Investing.com
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
After-hours movers: Edwards Lifesciences, Intel, Deckers Brands and more By Investing.com - Investing.com Canada
Edwards Lifesciences Corp Reports Q2 Revenue of $1.53 Billion, E - GuruFocus
Edwards Lifesciences shares leap 7% on strong Q2 results, sales growth guidance - Investing.com
Edwards Lifesciences Corp. Reports Retreat In Q2 Income - Nasdaq
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):